pharmaceutical investing Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy
Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
EnerCom Announces SM Energy as a Keynote Speaker at the 31st EnerCom Denver - The Energy Investment Conference, on August 19, 2026, in Denver, Colorado
